The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab
Open Access
- 21 September 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Archiv für dermatologische Forschung
- Vol. 298 (7), 329-338
- https://doi.org/10.1007/s00403-006-0694-9
Abstract
A large-scale, pooled analysis of safety data from five Phase III clinical trials (including open-label extensions of two of these studies) and two Phase III open-label clinical trials of efalizumab was conducted to explore whether arthropathy adverse events (AEs) were associated with efalizumab treatment in patients with moderate-to-severe chronic plaque psoriasis. Data from patients who received subcutaneous injections of efalizumab or placebo were stratified for analysis into phases according to the nature and duration of treatment. These included: the ‘first treatment’ phase (0–12-week data from patients who received either efalizumab, 1 mg/kg once weekly, or placebo in the five placebo-controlled studies); the ‘extended treatment’ phase (13–24-week data from seven trials for all efalizumab-treated patients); and the ‘long-term treatment’ phase (data from efalizumab-treated patients who received treatment for up to 36 months in two long-term trials). Descriptive statistics were performed and the incidence of arthropathy AEs per patient-year was calculated using 95% confidence intervals (CIs). During the first treatment phase, a similar proportion of patients had an arthropathy AE in the efalizumab group (3.3%; 58/1740 patients) compared with the placebo group (3.5%; 34/979 patients); the incidence of arthropathy AEs per patient-year was 0.15 in the efalizumab group (95% CI 0.11–0.19) and 0.16 in the placebo group (95% CI 0.11–0.22). Analysis of first treatment phase data from one study (n = 793) showed that the incidence of psoriatic arthropathy per patient-year was lower in efalizumab-treated patients (0.10; 95% CI 0.05–0.18) than in those given placebo (0.17; 95% CI 0.08–0.30). During the extended treatment phase, the incidence of arthropathy remained low (0.17; 95% CI 0.14–0.22). Data from two long-term studies showed that there was no increase in the incidence of arthropathy AEs over time in patients treated with efalizumab for up to 36 months. Patients who had an arthropathy AE during treatment with efalizumab appeared to be more likely to have a history of arthropathy prior to treatment. Efalizumab does not appear to increase the risk of arthropathy AEs compared with placebo.Keywords
This publication has 21 references indexed in Scilit:
- Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trialJournal of the American Academy of Dermatology, 2006
- Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisJournal of the American Academy of Dermatology, 2006
- Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trialInternational Journal of Dermatology, 2006
- Alefacept: a safety profileExpert Opinion on Drug Safety, 2005
- Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trialJournal of the American Academy of Dermatology, 2005
- Quality of Life and Prevalence of Arthritis Reported by 5,795 Members of the Nordic Psoriasis AssociationsActa Dermato-Venereologica, 2002
- Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking.Journal of Investigative Dermatology, 2000
- Leukocyte membrane adhesion proteins LFA-1, CR3 and p150,95: A review of functional and regulatory aspectsResearch in Immunology, 1989
- Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells.The Journal of cell biology, 1988
- The Lymphocyte Function Associated LFA-1, CD2, and LFA-3 Molecules: Cell Adhesion Receptors of the Immune SystemAnnual Review of Immunology, 1987